FDA Announces Oncology Center of Excellence
The U.S. Food and Drug Administration (FDA) recently announced, through the Office of Health and Constituent Affairs, that it has established the Oncology Center of Excellence (OCE). Longtime FDA official, Richard Pazdur, MD, has been named to lead the division as its first director. The OCE will make oncology “the first disease area to have a coordinated clinical review of drugs, biologics and devices across the agency’s three medical product centers,” according to the FDA.
Statin Use May Improve Overall Survival From Multiple Myeloma
A new study has found that use of statin medications in patients with multiple myeloma was associated with a decreased risk of all-cause and cancer-specific mortality. The findings were published in the Journal of Clinical Oncology.
Palbociclib Plus Letrozole Improves Survival in Advanced Breast Cancer
An Oncology Nursing Overview of New Immune Checkpoint Inhibitors
MABp1 May Be Effective for Metastatic Colorectal Cancer
Maintenance Treatment May Prolong Progression-Free Survival in Ovarian Cancer
Pembrolizumab Associated With Long-Term Survival in Advanced Melanoma
New Class of Drugs Shows Promise in Treatment-Resistant Prostate Cancer
What Nurses Need to Know About Talimogene Laherparepvec for Advanced Melanoma
Blinatumomab May Induce Remission in Patients With Relapsed or Refractory ALL
Low-Dose Metformin May Reduce Risk of Colorectal Adenomas
Discarded Excess U.S. Cancer Drugs Cost $1.8 Billion per Year
FDA Approves Venetoclax for CLL
FDA Approves Defibrotide Sodium for Hepatic Veno-Occlusive Disease
FDA Approves Crizotinib for ROS1-Positive Lung Cancer
FDA Approves New Indication for Everolimus
FDA Approves New Indication for Obinutuzumab
On February 26, 2016, the U. S. Food and Drug Administration approved obinutuzumab (Gazyva® Injection, Genentech, Inc.) for use in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen. Obinutuzumab was previously approved for use in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia.